Athena Athena

X
[{"orgOrder":0,"company":"Maxima Pharmaceuticals","sponsor":"Medisca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medisca Acquires all IP assets of Maxima Pharmaceuticals Including the DIFFUSIMAX\u00ae Brand","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Maxima Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Acquisition includes, DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.

            Lead Product(s): Pluronic Lecithin

            Therapeutic Area: Dermatology Product Name: Diffusimax

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Medisca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY